Eurobio Scientific Expands Oncology Portfolio with Genomic Assays

Eurobio Scientific has enhanced its oncology diagnostics capabilities by introducing new genomic assays designed for urothelial carcinoma and cancer of unknown primary origin. These additions aim to provide more precise diagnostic information, supporting clinicians in treatment planning for these complex conditions.

The company is also moving forward with the acquisition of CareDx's transplant laboratory product division, following a definitive agreement. This strategic acquisition is expected to bolster Eurobio Scientific's presence in the transplant diagnostics market, offering new tools for post-transplant patient monitoring and rejection management.

Recent activities, including the acquisition of Voden Medical Instruments S.p.A.'s Life Science unit and Quimark SRL, indicate Eurobio Scientific's focus on expanding its product portfolio and geographical reach within the diagnostics sector. The company seeks to integrate diverse expertise and innovative solutions to improve patient outcomes.

Partnerships, such as the one with Biovica that expanded its oncology portfolio, are also a key part of Eurobio Scientific's growth strategy. These initiatives collectively support the company's objective to advance diagnostic technology and contribute to better healthcare globally.